Panretinal Photocoagulation (PRP)
Sponsors
Hermann Eye Center, José Cunha-Vaz, Association for Innovation and Biomedical Research on Light and Image, Baqiyatallah Medical Sciences University, Jaeb Center for Health Research
Conditions
Diabetes Mellitus Type IDiabetes Mellitus Type IIDiabetes Mellitus, Type 2Diabetic RetinopathyHigh Risk Proliferative Diabetic RetinopathyIris NeovascularizationProliferative Diabetic Retinopathy (PDR)
Phase 1
Phase 2
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.
CompletedNCT01281098
Start: 2010-03-31End: 2013-02-28Updated: 2015-03-19
Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy
CompletedNCT01280929
Start: 2010-09-30End: 2013-12-31Updated: 2015-10-08
Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.
CompletedNCT01941329
Start: 2014-04-30End: 2017-10-31Target: 94Updated: 2018-05-14